IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Title : METHODS FOR PRODUCING ANTIBODIES

MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a/2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patent application publications can be provided upon request. An English translation of foreign language reference AD is not included, since it is a member of the patent family of English language reference AC.

This statement is being filed before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050, referencing Attorney Docket No. 14875-154US).

Respectfully submitted,

Reg. No. 34,819

Date: March 29, 2007	/Janis K. Fraser/
	Janis K. Fraser, Ph.D., J.D.

Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110 Telephone: (617) 542-5070 Facsimile: (617) 542-8906

21580818 doc

			Direct _1_ OI _2_
Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
Supplemental Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Taro Miyazaki et al.	
		Filing Date April 28, 2006	Group Art Unit 1645

U.S. Patent Documents						
				Filing Date If Appropriate		
	AA	2004/0219643	11/04/2004	Winter et al.		
	AB	2006/0159673	07/20/2006	Kojima		

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Translation	
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	AC	CA 2 331 641	11/11/1999	Canada				
	AD	DE 198 19 846	11/11/1999	Germany			see AC	
	AE	EP 0 774 511	05/21/1997	EPO				

	Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig.	Document			
	AF	Andris-Widhopf et al., "Methods for the generation of chicken monoclonal antibody fragments by phage display," J. Immunol. Methods, 242:159-181 (2000)			
	AG	De Jonge et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments," Mol. Immunol., 32:1405-1412 (1995)			
	AH	DeNardo et al., "Anti-HLA-DR/anti-DOTA Diabody Construction in a Modular Gene Design Platform: Bispecific Antibodies for Pretargeted Radioimmunotherapy," Cancer Biother. Radiopharm, 16:525-535 (2001)			
	AI	Goldstein et al., "Cytolytic and Cytostatic Properties of an Anti-Human FeyRI (CD64) × Epidermal Growth Factor Bispecific Fusion Protein," J. Immunol., 158:872-879 (1997)			
	ΑJ	Holliger et al., "Diabodies": Small bivalent and bispecific antibody fragments," Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)			
	AK	Hoogenboom et al., "Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains," Nucleic Acids Res., 19:4133-4137 (1991)			
	AL	Hudson et al., "High avidity scFv multimers; diabodies and triabodies," J. Immunol. Methods, 231:177-189 (1999)			
	AM	Kipriyanov et al., "Effect of Domain Order on the Activity of Bacterially Produced Bispecific Single-chain Fv Antibodies." J. Mol. Biol., 330:99-111 (2003)			
	AN	Krebber et al., "Reliable cloning of functional antibody variable domains from hybridomas and splien cell repertoires employing a recognicered phage display system," J. Immunol. Methods, 201:35-55 (1997)			
	AO	Kurucz et al., "Retargeting of CTL by an Efficiently Refolded Bispecific Single-Chain Fv Dimer Produced in Bucteria," J. Immunol, 154:4576-4582 (1995)			
	AP	Little et al., "Of mice and men: hybridoma and recombinant antibodies," Immunol. Today, 21:364-370 (2000)			
	AQ	McGuinness et al., "Phage diabody repertoires for selection of large numbers of bispecific antibody fragments," Nat. Biotechnol., 14:1149-1154 (1996)			

Examiner Signature

Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 14875-154US1	Application No. 10/560,098
Supplemental Information Disclosure Statement by Applicant		Applicant Taro Miyazaki et al.	
(Use several s	heets if necessary)	Filing Date April 28, 2006	Group Art Unit 1645

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Desig. Initial ID Document		
	AR	Merchant et al., "An efficient route to human bispecific IgG," Nat. Biotechnol., 16:677-681 (1998)
	AS	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments," Immunotechnology, 3:83-105 (1997)
	AT	Tang et al., "Selection of Linkers for a Catalytic Single-chain Antibody Using Phage Display Technology," J. Biol. Chem., 271:15682-15686 (1996)
	AU	Turner et al., "Importance of the linker in expression of single-chain Fv antibody fragments: optimisation of peptide sequence using phage display technology," J. Immunol. Methods, 205:43-54 (1997)
	AV	Völkel et al., "Optimized linker sequences for the expression of monomeric and dimeric bispecific single-chain diabodies," Protein Eng., 14:815-823 (2001)

Examiner Signature	Date Considered			
EXAMINER: Initials citation considered. Draw line through citation if no	t in conformance and not considered. Include copy of this form with			
next communication to applicant.				